The study was to compare the effects of amlodipine (calcium channel antagonist), chlorthalidone (diuretic), and placebo in adults more than 50 years of age with stage l isolated systolic hypertension (ISH). After a 4-week placebo run-in phase, 150 patients were randomly assigned in a double-blind fashion to treatment with 5 mg of amlodipine (n ϭ 48), 15 mg of chlorthalidone (n ϭ 50), or placebo (n ϭ 52). Patients who failed to meet the systolic blood pressure (BP) reduction goal by week 4 had their dose increased to 10 mg of amlodipine or 30 mg of chlorthalidone, and maintained at this increased dose for 12 weeks. Results showed a mean reduction (mean Ϯ SD) in sitting systolic BP from baseline to the last treatment visit of Ϫ14.6 Ϯ 12.2 mm Hg (95% confidence interval [CI] Ϫ18.2, Ϫ11.0), Ϫ14.0 Ϯ 13.46 mm Hg (95% CI Ϫ17.8, Ϫ10.2), and Ϫ3.4 Ϯ 11.83 mm Hg (95% CI Ϫ6.7, Ϫ0.1) for the amlodipine, chlorthalidone, and the placebo treatment groups, respectively. Both active treatments showed significantly greater reductions than the placebo group (P Յ .001), but were not significantly different from each other. Sixty-seven percent of the amlodipine, 69% of the chlorthalidone, and 25% of the placebo-treated patients reached the protocol defined systolic BP goal (P ϭ .001). Both active treatment groups showed a trend of better systolic BP response in older patients (Ն65 years). Secondary efficacy measures including pulse pressure, standing systolic, diastolic, and the 24-h ambulatory BP were also statistically significantly improved for both active treatments at the end of treatment, except for chlorthalidone in standing diastolic BP. Adverse events that occurred during the study were as expected and were well tolerated. The results of this study support the efficacy and safety of amlodipine and chlorthalidone for the treatment of stage l ISH during 20 weeks of treatment. Am J Hypertens 2002;15:31-36
H
ypertension affects approximately 50 million Americans yearly and is the main treatable contributor to the morbidity and mortality of cardiovascular disease (CVD). 1 Treatment has historically focused on controlling diastolic blood pressure (DBP). However, elevated systolic blood pressure (SBP) and pulse pressure (PP) have been shown to be strong predictors of cardiovascular events, 2, 3 and this has been supported by numerous observational studies of isolated systolic hypertension (ISH) such as Framingham Heart Study and the Multiple Risk Factor Intervention Trial (MRFIT). The benefits of treatment for those with ISH with SBP Ͼ160 mm Hg was shown in the Systolic Hypertension in the Elderly Program (SHEP), Syst-China (Systolic Hypertension in China), and Syst-EUR (Systolic Hypertension in Europe), three large clinical trials. It is likely that with advancing age (Ͼ50 years), the increase in SBP, decrease in DBP, and corresponding increase in PP reflects a stiffening of the blood vessels and reduced arterial compliance. [4] [5] [6] Stage I ISH, defined as a SBP of 140 to 159 mm Hg in conjunction with normal DBP of Ͻ90 mm Hg, is the most common type of untreated hypertension among adults more than 60 years old. 7, 8 The Framingham Heart Study reported that individuals with stage l ISH are at greater risk than normotensive individuals for abnormalities in cardiac structure and function, with 80% of patients with stage l ISH progressing to more severe hypertension over the course of a 20-year follow-up period. 7, 9 In the present study, amlodipine (Norvasc), a dihydropyridine calcium antagonist (CA) was compared to chlorthalidone (Thalitone), a diuretic, and placebo for the management of patients with stage I ISH.
Patients and Methods
This randomized, multicenter, double-blind, parallelgroup study compared the efficacy of amlodipine (Pfizer Inc., New York, NY) versus chlorthalidone (Horus Therapeutics, Inc., Rochester, NY) and placebo for the treatment of stage l ISH in male and female patients Ն50 years of age. A diagnosis of stage l ISH was defined as the average of two sitting SBP in the range of 140 to 159 mm Hg on two consecutive visits during the placebo run-in phase. Patients were excluded if they had any form of secondary hypertension; had significant hematologic, hepatic or renal disease; had insulin-dependent diabetes; had a history of myocardial infarction, cerebrovascular accident, or coronary artery surgery within the 6 months before the trial.
Each patient was randomly assigned to either amlodipine (5 mg once daily), chlorthalidone (15 mg once daily), or placebo after a 4-week placebo run-in phase. During the first 8-week of treatment (titration phase), the dosage could be doubled after 4 weeks of treatment if the SBP goal (discussed later) was not reached. After this titration phase, patients were maintained at their designated dose for an additional 12 weeks. Goal BP was defined as: 1) an average sitting SBP between 150 and 159 mm Hg at the end of the placebo run-in phase, which was reduced to Ͻ140 mm Hg after treatment; or 2) an average sitting SBP between 140 and 149 mm Hg at the end of the placebo run-in phase, which was reduced 10 mm Hg from baseline after treatment.
The primary efficacy outcome variable was average sitting SBP. The secondary efficacy variables were: number of patients reaching sitting SBP goal, PP, standing SBP, sitting and standing DBP, and 24-h ambulatory BP monitoring, which included SBP and DBP, PP, mean arterial pressure (MAP), and peak-to-trough ratios of BP measurements.
Statistical Analysis
Baseline demographic variables were summarized by treatment group. For continuous baseline variables, comparability of the treatment groups was assessed using analysis of variance (ANOVA) techniques with terms for site and treatment. For categoric variables, baseline differences among treatment groups were assessed with Cochran-Mantel-Haenszel 2 tests, stratified by site. The efficacy and safety analyses were performed on an intent-to-treat (ITT) population, which included all randomized patients who took at least one dose of study medication. For the last treatment visit analyses, the lastobservation-carried-forward (LOCF) method was used. A similar ANOVA model, as described, including terms for site and treatment, was used to assess change from baseline in office BP measurements within as well as among treatment groups. Pairwise comparisons between treatments were performed within the framework of ANOVA, when a significant overall F-test (P Յ .05) was obtained. The comparability of the percentage of subjects reaching goal BP at the end of the titration and maintenance phase was assessed using the Cochran-Mantel-Haenszel 2 tests, adjusted for site. To explore the possible drug effect on different age groups, one group analysis was performed: for each efficacy variable, patients in each treatment group were stratified into one of two groups based on age at baseline: 1) Ն65 years of age, and 2) Ͻ65 years of age. All statistical tests were two-sided and assessed at the 0.05 alpha level. The study was statistically powered for the primary efficacy variable, average sitting SBP. The results of secondary efficacy variables need to be interpreted with caution and should only be considered as exploratory.
Results

Patient Disposition
Two hundred twenty-four patients with stage I systolic hypertension were studied at nine investigational sites throughout the United States between April 1995 and September 1998. Of the 204 patients who entered the placebo run-in phase, 150 were randomized to receive active drug treatment. Of the 54 patients who discontinued treatment, 31 did not meet entrance criteria, 12 withdrew consent, 4 were lost to follow-up, 2 had adverse events, and 5 had other reasons. All three treatment groups had similar baseline characteristics. These included age, sex, body mass index, race, BP, cholesterol and potassium levels, smoking habits, and prior drug treatment (Table 1) . At baseline there were no significant differences in SBP (148.0, 148.1, or 149.1 mm Hg) or DBP (80.2, 81.4, or 81.3 mm Hg) for the amlodipine, chlorthalidone, or placebo treatment groups, respectively.
Sixteen patients did not complete the study. Five patients (3 amlodipine, 2 chlorthalidone) discontinued due to adverse events. The remaining patients either withdrew consent (4 amlodipine, 1 chlorthalidone, 3 placebo), had a protocol violation (1 chlorthalidone), were lost to follow-up (1 chlorthalidone), or were withdrawn for another reason (1 placebo). The median duration of therapy for all patients was 140 days.
Efficacy
The primary end point of average sitting SBP mean change from baseline to the last treatment visit (LOCF analysis) is presented in Fig. 1 . There were statistically significant mean changes (mean Ϯ SD) from baseline in average sitting SBP of Ϫ14.6 Ϯ 12.20 mm Hg (95% confidence interval [CI] Ϫ18.2, Ϫ11.0) in the amlodipine treatment group, Ϫ14.0 Ϯ 13.46 mm Hg (95% CI Ϫ17.8, Ϫ10.2) in the chlorthalidone treatment group, and Ϫ3.4 Ϯ 11.83 mm Hg (95% CI Ϫ6.7, Ϫ0.1) in the placebo treatment group. The mean reductions in the active treatment groups were significantly greater than the reduction in the placebo group (P Յ .001). Overall, 67% of amlodipinetreated patients, 69% of chlorthalidone-treated patients, and 25% of placebo-treated patients reached average sitting SBP goal at the end of maintenance. The difference between the active treatment groups and the placebo group was statistically significant (P Յ .001); however, there was no significant difference between the two active treatment groups. Changes from baseline average sitting SBP were also evaluated in two age groups made up of patients Ͻ65 years old and those Ն65 years old. The older patients in both active treatment groups seems to have shown a trend of better response to treatment as evidenced by a relative larger mean reduction from baseline in average sitting SBP than that observed for the younger patients (Table 2 ). There was no statistically significant difference between placebo and two active treatment groups in the younger patients. However, due to the small sample size, the result should be considered as exploratory.
There was a significant reduction in mean sitting and standing PP measurements in the active treatment groups compared with the placebo treatment group at the last treatment visit (P Ͻ .05). The mean reductions in standing SBP and sitting DBP in the amlodipine and chlorthalidone treatment groups were also significantly greater than the reductions observed in the placebo treatment group at the last treatment visit (P Յ .001). The mean reduction of standing DBP in the chlorthalidone treatment group was not statistically significant (P ϭ .119). There was no statistically significant difference between the amlodipine and chlorthalidone treatment groups in all secondary efficacy endpoint measurements ( Table 3) .
The baseline ambulatory SBP was highest in the hours between 6 AM and 7 PM for all groups. Both amlodipinetreated and chlorthalidone-treated patients showed a statistically significant decline from baseline ambulatory SBP throughout most or all of the 24-h period, with the greatest reduction between 2:00 AM and 10:00 AM (Fig. 2) . Most hourly mean changes of SBP from baseline in the placebo treatment group were not statistically significant. There was no statistically significant difference between the two active treatments in the ambulatory SBP hourly mean reduction from baseline during the 24-h period. Ambulatory hourly mean reductions in DBP were statistically significant from baseline for the majority of the 24-h monitoring period in the amlodipine and chlorthalidone treatment groups (Fig. 3) . Similar results were also observed for ambulatory hourly mean reductions in PP and MAP.
Safety
The incidence of adverse events was similar in the amlodipine (52.1%), chlorthalidone (52%), and placebo (59.6%) treatment groups. Discontinuation rates due to an adverse event were similar for both active treatment groups: 6.3% in the amlodipine treatment group and 4.0% in the chlorthalidone treatment group. There were no discontinuations due to adverse events in the placebo group. In general, both active drugs were well tolerated. As expected, peripheral edema occurred more often in the amlodipine treatment group (10.4%) and hyperglycemia (4%) and hypokalemia (4%) were more common in the chlorthalidone treatment group.
One patient, a 71-year-old man treated with chlorthalidone, was found to have an electrocardiographic abnormality of possible anteroseptal infarct and hypokalemia (2.9 mEq/L) on final study visit (baseline potassium level for this patient was 4.1 mEq/L). Upon advice he sought medical attention. Two days after the final study visit, he was admitted to the hospital and underwent a coronary artery bypass graft. Three days later the patient experienced cardiac arrest and died. Cause of death was multiple cardiac arrhythmias due to coronary artery disease. In the investigator's opinion, the event was not related to study medication.
Discussion
In the present study, the effectiveness of amlodipine, chlorthalidone, and placebo was compared in patients * P value for treatment effect from ANOVA (using least square means) with terms for site and treatment. † P value for change from baseline from ANOVA. Mean changes (mean Ϯ SD) from baseline to the last treatment visit compared by age groups. more than 50 years of age with stage I ISH. The primary end point, average sitting SBP, and most of the secondary end point measures, including PP, standing SBP, DBP, and 24-h ambulatory BP, were significantly improved from baseline in both active treatment groups (only changes in standing DBP for the chlorthalidone treatment group was not statistically significant). The majority of patients treated with amlodipine (67%) or chlorthalidone (69%) reached BP goal at the end of maintenance as compared to the placebo group (25%). Overall, the mean changes from baseline in both active treatment groups were significantly greater than the mean changes from baseline in the placebo treatment group. No significant differences between the two active treatment groups were observed for the primary or secondary end points. The Framingham Heart Study reported that 18% of 2767 participants 65 years of age or older had stage I ISH. 7 The importance of treating ISH in the older population was demonstrated in three ISH trials, Syst-EUR, SystChina, and SHEP trials. In a meta-analysis of these trials, totaling 11,600 patients Ն60 years of age treated with either CA or diuretics, it was shown that by lowering the SBP, the number of strokes and cardiovascular mortality were reduced by 37% and 25%, respectively. 10 -16 The SHEP trial also showed that an increase in PP was directly related to higher stroke and mortality in older patients. It was noted that each 10 mm Hg increase in PP demonstrated an 11% increase in stroke risk and a 16% increase in risk of all-cause mortality. 17 Recently two new trials using calcium channel blockers have also shown favorable results in older patients with systolic hypertension. The Swedish Trial in Old Patients with Hypertension-2 study (STOP Hypertension-2) and the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT) found that the choice of drug can be decided by BP response and tolerability. Both conventional and newer antihypertensive drugs demonstrated similar effects in lowering BP for the prevention of cardiovascular events. 18, 19 The Joint National Committee (JNC VI) has recommended diuretics and long-acting dihydropyridines CA as initial drug choices for the treatment of ISH in older persons. 8 Although the reduction of morbidity and mortality with active treatment for stage I ISH has not as yet been demonstrated, the present study shows that both amlodipine and chlorthalidone can significantly reduce SBP, PP, DBP, and 24-h ambulatory BP in patients with stage I ISH.
FIG. 2.
Effect on 24-h ambulatory systolic blood pressure (mm Hg) change from baseline at week 24 (end of maintenance) (amlodipine versus chlorthalidone versus placebo).
FIG. 3.
Effect on 24-h ambulatory diastolic blood pressure (mm Hg) change from baseline at week 24 (end of maintenance) (amlodipine versus chlorthalidone versus placebo).
